We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Figure 1

Figure 1. From: INTRAVENOUS N-ACETYLCYSTEINE IMPROVES TRANSPLANT-FREE SURVIVAL IN EARLY STAGE NON-ACETAMINOPHEN ACUTE LIVER FAILURE.

Study design. A total of 820 patients were screened, leading to 173 patients enrolled in the final study.

WM Lee, et al. Gastroenterology. ;137(3):856-864.e1.
2.
Figure 2

Figure 2. From: INTRAVENOUS N-ACETYLCYSTEINE IMPROVES TRANSPLANT-FREE SURVIVAL IN EARLY STAGE NON-ACETAMINOPHEN ACUTE LIVER FAILURE.

Kaplan-Meier curve for each group (treatment by coma category) was used to show overall survival to 365 days. In separate analyses, patients in the NAC I–II group demonstrated significantly higher survival than either Placebo III–IV (p = 0.012) or NAC III–IV (p = 0.002). Number of patients with censored data prior to 365 days: 14 in NAC I–II, 5 in NAC III–IV, 12 in Placebo I–II, 7 in Placebo III–IV.

WM Lee, et al. Gastroenterology. ;137(3):856-864.e1.
3.
Figure 3

Figure 3. From: INTRAVENOUS N-ACETYLCYSTEINE IMPROVES TRANSPLANT-FREE SURVIVAL IN EARLY STAGE NON-ACETAMINOPHEN ACUTE LIVER FAILURE.

Kaplan-Meier curves for each group (treatment by coma category) showing transplant-free survival to 365 days. Patients in the NAC I–II group demonstrated significantly higher transplant-free survival than the other three groups (largest p = 0.017). Number of patients with censored data prior to 365 days: 10 in NAC I–II, 2 in NAC III–IV, 5 in Placebo I–II, 2 in Placebo III–IV. Note: 2 patients in the NAC III–IV group were censored, one at day34 and the other at day 58.

WM Lee, et al. Gastroenterology. ;137(3):856-864.e1.
4.
Figure 4

Figure 4. From: INTRAVENOUS N-ACETYLCYSTEINE IMPROVES TRANSPLANT-FREE SURVIVAL IN EARLY STAGE NON-ACETAMINOPHEN ACUTE LIVER FAILURE.

Kaplan-Meier curves for each group (treatment by coma category) showing number of days to transplantation to 365 days. Patients in the NAC I–II group demonstrated significantly longer time to transplantation than the other three groups (largest p = 0.032). Number of patients with censored data prior to 365 days: 10 in NAC I–II, 2 in NAC III–IV, 5 in Placebo I–II, 3 in Placebo III–IV. Note: 2 patients in the NAC III–IV group were censored, one at day34 and the other at day 58.

WM Lee, et al. Gastroenterology. ;137(3):856-864.e1.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk